ImmunityBio, Inc. (NASDAQ: IBRX) saw its stock price soar 5.26% in Tuesday's intraday trading session following the release of its full-year 2024 financial results.
While the biotechnology company reported a net loss of $413.6 million for the year, this figure represented a 29% narrowing of losses compared to the previous year. Additionally, ImmunityBio's earnings per share (EPS) surpassed analyst expectations, despite revenue falling short of estimates.
Looking ahead, the company forecasts an impressive 55% annual revenue growth on average over the next three years, outpacing the 20% growth forecast for the broader American biotechs industry. However, investors are advised to consider the four warning signs identified by analysts, including three significant ones, which may impact the company's future performance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.